80 completed, 31 recruiting, 10 not yet recruiting, 10 terminated. 156 Phase 2, 21 Phase 1, 10 Phase 3.
Follow Alcohol Use Disorder: new trials by email Literature Review of Alcohol Use Disorder trials Research Report on Alcohol Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daridorexant for Alcohol Use Disorder Daridorexant 50 mg, Placebo - Alcohol Use Disorder | Phase 2 | Not yet recruiting | Johns Hopkins University | 150 | 2027-01-01 | 2026-04-20 |
| N-Acetylcysteine for Bipolar and Alcohol Use Disorders N-acetyl cysteine, Placebo - Bipolar Disorder, Alcohol Use Disorder | Phase 2 | Not yet recruiting | Medical University of South Carolina | 70 | 2027-01-01 | 2026-11-03 |
| Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder Kenetik, magnetic resonance imaging scan, Alcohol bar lab - Alcohol Use Disorder, Ketosis | Phase 2 / Phase 3 | Recruiting | University of Pennsylvania | 60 | 2026-12-01 | 2026-10-21 |
| Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder Psilocybin - Alcohol Use Disorder | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 36 | 2026-11-15 | 2026-10-09 |
| Study on Thiamine Supplementation to REduce braiN Injury Associated With Chronic Alcohol Use in Outpatients With Alcohol Use Disorder Thiamine - Alcohol Use Disorder | Phase 2 | Recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 60 | 2026-11-02 | 2026-11-06 |
| Combination Therapy for Alcohol Use Disorder Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets) - Alcohol Use Disorder | Phase 2 | Not yet recruiting | Johns Hopkins University | 45 | 2026-11-01 | 2026-10-01 |
| Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients Sodium Acetate, Placebo - Alcohol Withdrawal, Alcohol Abstinence | Phase 1 / Phase 2 | Not yet recruiting | University of Colorado, Denver | 75 | 2026-11-01 | 2026-10-30 |
| Methylphenidate and Response to Alcohol Cues Methylphenidate Pill, Placebo Pill - Alcohol Use Disorder | Phase 2 | Not yet recruiting | University of Florida | 50 | 2026-10-01 | 2026-08-20 |
| Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use Endotoxin, Placebo saline - Alcohol Use Disorder, Inflammatory Response | Phase 2 | Not yet recruiting | University of California, Los Angeles | 64 | 2026-09-01 | 2026-08-28 |
| Effects of Nimodipine on Alcohol Drinking Nimodipine, Placebo - Alcohol Use Disorder | Phase 2 | Not yet recruiting | Yale University | 40 | 2026-09-01 | 2026-07-02 |
| Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD Psilocybin, Inactive Placebo, Supportive therapy sessions - Alcohol Use Disorder | Phase 2 | Recruiting | NYU Langone Health | 200 | 2026-09-01 | 2026-09-02 |
| Daridorexant for People With Insomnia and Alcohol Use Disorder Study Daridorexant, Placebo, Brief Counseling - Alcohol Use Disorder, Insomnia | Phase 2 | Not yet recruiting | Sterling McPherson | 205 | 2026-09-01 | 2026-07-14 |
| Pilot Study: Effects of Nimodipine on Alcohol Drinking Nimodipine - Alcohol Use Disorder | Phase 2 | Not yet recruiting | Yale University | 5 | 2026-09-01 | 2026-03-17 |
| Tirzepatide in MetALD Tirzepatide, Placebo - Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder | Phase 2 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 120 | 2026-06-11 | 2026-08-12 |
| MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder Full Dose MDMA, MDMA-Assisted psychotherapy, Active Placebo Dose MDMA - Post Traumatic Stress Disorder, Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | VA Office of Research and Development | 80 | 2026-05-18 | 2026-06-02 |
| Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder Apremilast 60mg, Placebo - Alcohol Use Disorder | Phase 2 | Recruiting | Yale University | 80 | 2026-05-12 | 2026-10-30 |
| Cannabidiol and Alcohol Use Disorder Phenotypes Full-Spectrum Cannabidiol (CBD), Broad-Spectrum Cannabidiol (CBD), Placebo - Alcohol Use Disorder | Phase 2 | Recruiting | University of Colorado, Denver | 150 | 2026-04-21 | 2026-09-16 |
| Human Laboratory Study of Apremilast for Alcohol Use Disorder Placebo, Apremilast - Alcohol Use Disorder, Alcohol Misuse | Phase 2 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 100 | 2026-04-03 | 2026-05-01 |
| Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking Suvorexant 10 mg, Placebo - Alcohol Use Disorder | Phase 2 | Recruiting | Ohio State University | 250 | 2025-12-04 | 2026-09-21 |
| Tirzepatide for Alcohol Use Disorder Tirzepatide, Placebo injections - Alcohol Use Disorder, Obesity and Overweight | Phase 2 | Recruiting | University of Southern California | 42 | 2025-10-06 | 2025-10-14 |
Showing 20 of 156. Sign in to see all of them.
Alcoholism (156) · Alcohol Drinking (16) · Stress Disorders, Post-Traumatic (12) · Behavior, Addictive (8) · Substance-Related Disorders (7) · Alcohol-Related Disorders (6) · Depressive Disorder, Major (6) · Anxiety Disorders (4) · Marijuana Abuse (4) · Depression (3) · Ketosis (3) · Acquired Immunodeficiency Syndrome (2) · Alcohol Abstinence (2) · Bipolar Disorder (2) · Brain Concussion (2)
Chemically-Induced Disorders (155) · Mental Disorders (155) · Alcohol-Related Disorders (150) · Substance-Related Disorders (149) · Behavior (28) · Drinking Behavior (15) · Stress Disorders, Traumatic (12) · Trauma and Stressor Related Disorders (12) · Pathological Conditions, Signs and Symptoms (9) · Compulsive Behavior (8) · Impulsive Behavior (8) · Mood Disorders (8) · Depressive Disorder (6) · Nervous System Diseases (6) · Nutritional and Metabolic Diseases (5)
Psilocybin (11) · Sugars (9) · Ethanol (8) · Naltrexone (8) · Oxytocin (7) · Cannabidiol (6) · Ketamine (6) · Sodium Chloride (6) · Varenicline (5) · semaglutide (5) · Acetylcysteine (4) · Endotoxins (3) · Gabapentin (3) · Pioglitazone (3) · Tirzepatide (3)
Medical University of South Carolina (12) · University of California, Los Angeles (11) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (8) · University of Colorado, Denver (7) · Yale University (7) · Brown University (4) · Johns Hopkins University (4) · NYU Langone Health (4) · New York State Psychiatric Institute (4) · The Mind Research Network (4) · The Scripps Research Institute (4) · University of Pennsylvania (4) · VA Office of Research and Development (4) · Centre for Addiction and Mental Health (3) · The University of Texas Health Science Center, Houston (3)
United States (127) · Canada (5) · France (4) · Denmark (3) · Australia (2) · Bulgaria (2) · Sweden (2) · Switzerland (2) · Finland (1) · Germany (1) · Israel (1) · Norway (1) · Poland (1) · Romania (1) · Russia (1)
Lara Ray, PhD (7) · Barbara J. Mason, Ph.D. (4) · Joseph P Schacht, PhD (4) · Gihyun Yoon, MD (3) · Amy A Herrold, PhD BA (2) · Charles Marmar, MD (2) · Christian Hendershot, Ph.D. (2) · Corinde E Wiers, Ph.D. (2) · Corinde Wiers, Ph.D. (2) · E. Jennifer Edelman, MD, MHS (2) · Jack R Cornelius, M.D., M.P.H. (2) · Jin H Yoon, PhD (2) · Kirsten C Morley, PhD (2) · Lorenzo Leggio, M.D. (2)
PMID 15850502, PMID 19032530, PMID 19345510, PMID 22439295, PMID 27920321, PMID 29336496, PMID 29379114, PMID 29540927, PMID 30538599, PMID 32150232, PMID 32160422, PMID 32368793, PMID 32912290, PMID 33165153, PMID 33225963, PMID 34080890, PMID 34092158, PMID 34256607, PMID 34585396, PMID 34968106, PMID 35410938, PMID 35523943, PMID 36241352, PMID 36646315, PMID 38126709, PMID 38206930, PMID 38597214, PMID 38828963, PMID 39111388, PMID 39225670, PMID 39262902, PMID 39719161, PMID 39739971, PMID 39779270, PMID 39937469, PMID 40080609, PMID 40123107, PMID 40144690, PMID 40305022, PMID 40357520, PMID 40487775, PMID 40500407, PMID 40550124, PMID 40584152, PMID 40795937, PMID 41016625, PMID 41603979, PMID 42070571, PMID 42236678, PMID 42409408
P01AA029545 (2), P50AA012870 (2), 2015 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), 2025 (1), I01RX002916 (1), IK2RX000949 (1), K01AA026005 (1), K23AA029198 (1), K24AA025704 (1), K24AA026326 (1), P01AA027057 (1)